NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study.

Ther Adv Med Oncol · 2026 · PMC13009902 · PMID 41883864

Europe PMC DOI

hedged sentence

0.1220

closest p · 2.4× alpha

0.1220

boldest claim

The sentences

did not reach statistical significancep = 0.122not close (p > 0.1)

Rates of diarrhea and vomiting were numerically higher in the NALIRIFOX group but did not reach statistical significance (4.7% vs 1.3%, p = 0.122 and 7.8% vs 3.2%, p = 0.133, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.